AQP4 and myeloid sarcoma: The demonstration of significantly increased levels of IL-6 in comparison to MS in the CSF and serum of patients with NMO [17,18], particularly in AQP4 Ab-seropositive patients with severe disease activity [18], provides a rationale for the use of this drug in NMO.